Cookie settings

When you visit any website, that website may store or retrieve information about your browser, especially in the form of cookies. This information may relate to you, your preferences, your device, or it can be used to make the site work as you expect. This information usually doesn't identify you directly, but it allows you to get more personalized online content. In these settings, you can choose not to allow certain types of cookies. Click on the category headings to learn more and change your default settings. However, you should be aware that blocking certain cookies may affect your experience with the site and the services we may offer you.More info

Manage cookie settings

Necessary cookies

Always active

These cookies are necessary to ensure the functionality of the website and cannot be turned off in our systems. They are usually set up only in response to activities you perform that constitute a service-related request, such as setting privacy preferences, signing in, or filling out forms. You can set your browser to block or alert you to such cookies, in which case some parts of the site may not work.

Performance cookies

These cookies allow us to determine the number of visits and traffic sources so that we can measure and improve the performance of our site. They help us identify which sites are the most and least popular, and see how many visitors are moving around the site. All information that these cookies collect is aggregated and therefore anonymous. If you do not enable these cookies, we will not know when you visited our site.

In-silico design of anti-tumor inhibitors (Molecular docking)

Over the years many studies in chemistry have been devoted to searching for new drugs against different sorts of diseases. Cancer diseases are the case as well. In 1971 Judah Folkman (Harvard Medical School, Boston) published a theory in which he reported that every rapidly growing tissue needs a high amount of nutrients (especially oxygene). In other words, according to this theory all cancer tumors are angiogenesis-dependent. As Folkman believed, if we could stop a tumor from growing its own blood supply it would wither and die.

This is why inhibition of angiogenesis (new blood vessel creation) is a promising way to treat cancer diseases. Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) is considered one of the most interesting target molecules in contemporary medical research looking for possible methods of suppressing or almost slowing down the process of tumor neovascularization. Therefore, inhibition of VEGFR2 is the main goal of many recent studies in pharmaceutical and medicinal chemistry. New potent inhibitors of VEGFR2 can be obtained by means of several different ways.

Figure 1: Process of tumor angiogenesis

Figure 1: Process of tumor angiogenesis

In our research we use several computer based approaches to design (fragment-based design) or filter (mainly SAR screening and molecular docking) new organic molecules as potential inhibitors of VEGFR2 and to study their interactions with receptor’s binding site. We are looking for stronger interactions compared to those in known inhibitor-receptor complexes. By means of those methods we have proposed and subsequently theoretically tested several sets of newly-designed structures with presumed inhibitory effect on VEGFR2.

Figure 2: Potential inhibitors of VEGFR2 in its binding site

Figure 2: Potential inhibitors of VEGFR2 in its binding site